title: Adverse cardiovascular effects of partial correction of renal anemia by recombinant human erythropoietin.
abstract: The analysis of the hemodynamic parameters involved in the regulation of blood pressure during correction of anemia shows - although peripheral resistance and cardiac output behave qualitatively as in the nonuremic patient - that the extent of change may be inadequate resulting in an increased blood pressure. The underlying mechanisms are not yet fully understood but to a greater part may be related to preexisting pathology due to a history of long-lasting hypertension. To avoid cardiovascular complications under rhEPO therapy the following should be considered: patients with a history of hypertension, even if they are normotensive in the anemic state, are at a higher risk for developing hypertension under rhEPO. Hypertensive complications may be rare events when anemia is corrected slowly. Further studies will demonstrate whether in addition to the benefit of a very low maintenance dose of rhEPO subcutaneous administration will also contribute to the reduction of the incidence of hypertension.
authors.affiliation: Abteilung für Nephrologie, Medizinische Hochschule Hannover, FRG.
authors.forename: U
authors.initials: U
authors.lastname: Frei
authors.forename: B
authors.initials: B
authors.lastname: Nonnast-Daniel
authors.forename: J
authors.initials: J
authors.lastname: Schäffer
authors.forename: K M
authors.initials: KM
authors.lastname: Koch
mesh_terms: D000740:Anemia / Q000503:physiopathology / Q000628:therapy*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin